GRAIL, Inc.
NASDAQ:GRALMedical - Diagnostics & Research
+$1.90 today
- Market cap
- $4.59B
- Beta
- 3.16
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$9.73
Volume 0.62M
Average 0.77M
GRAL Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
GRAIL, Inc.NASDAQ: GRAL
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $47.43M rose 1.7% year over year, ahead of the -15.8% change in trailing-twelve-month research & development. Sequentially, it fell 1.2% from the prior quarter. Over 3 fiscal years it compounded at -15.9% a year.
Context
- Research & development amounted to 133.0% of revenue in FY2025, down 123.6 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1.7% holds above the trailing-twelve-month pace of -15.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 195.79M USD
- Year-over-year change
- -39.3%
- 4-year CAGR
- -19.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 195.79M | -39.3% |
| FY2024 | 2024-12-31 | 322.38M | -4.8% |
| FY2023 | 2023-12-31 | 338.75M | +2.8% |
| FY2022 | 2022-12-31 | 329.58M | -28.4% |
| FY2021 | 2021-12-31 | 460.21M | — |
Research & Development vs competitors
How GRAL compares with its peers on the latest reported figures
- GRAL's LTM Jun 2026 research & development of $190.99M is the 3rd highest of the 10 companies compared; the peer median is $59.21M.
- Its year-over-year change of -15.8% is the lowest of 10, against a peer median of +9.5%.
- Research & development amounts to 115.6% of revenue for GRAL, versus a peer median of 17.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $787.38M | +56.9% | +25.4% | 29.1% | |
| LTM Sep 2026 | $386.67M | +7.6% | -0.9% | 30.2% | |
| LTM Jun 2026 | $190.99M | -15.8% | -15.9% | 115.6% | |
| LTM Mar 2026 | $106.4M | -7.7% | +7.7% | 12.8% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $83.32M | +64.3% | -5.8% | 18.3% |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $59.21M | +38.6% | — | 14.9% |
| LTM Mar 2026 | $55.69M | +11.9% | +23.1% | 17.4% | |
| LTM Mar 2026 | $53.69M | +5.8% | +4.9% | 15.8% | |
| LTM Mar 2026 | $52.16M | +6.9% | -8.2% | 80.9% | |
| LTM Jun 2026 | $38.17M | +9.5% | +6.9% | 5.0% | |
| Peer median (excluding GRAL) | $59.21M | +9.5% | +5.9% | 17.4% | |
Competitors are the stored peer set for GRAL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 14.61M | 55.55M | 93.11M | 125.6M | 147.17M |
| Cost of Revenue | 114.62M | 172M | 188.72M | 203.62M | 209.75M |
| Gross Profit | (100M) | (116.45M) | (95.61M) | (78.02M) | (62.57M) |
| Gross Margin | -684.4% | -209.6% | -102.7% | -62.1% | -42.5% |
| Research & Development | 460.21M | 329.58M | 338.75M | 322.38M | 195.79M |
| Selling, General & Admin | 234.06M | 296.44M | 362.56M | 367.82M | 275.8M |
| Operating Expenses | 1.17B | 5.33B | 1.42B | 2.11B | 471.59M |
| Depreciation & Amortization | 58.45M | 154.76M | 158.7M | 158.06M | 156.34M |
| EBITDA | (1.21B) | (587.7M) | (638.22M) | (610.17M) | (378.16M) |
| EBITDA Margin | -8259.0% | -1058.0% | -685.5% | -485.8% | -257.0% |
| Operating Income | (1.27B) | (5.44B) | (1.52B) | (2.19B) | (534.16M) |
| Operating Margin | -8659.6% | -9798.2% | -1627.6% | -1743.0% | -363.0% |
| Interest Income | 332K | 1.74M | 7.95M | 26.73M | 28.65M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 90K | 1.5M | 7.75M | 26.8M | (341K) |
| Income Before Tax | (1.27B) | (5.44B) | (1.51B) | (2.16B) | (534.5M) |
| Pre-Tax Margin | -8659.0% | -9795.5% | -1619.3% | -1721.7% | -363.2% |
| Income Tax Expense | (17.48M) | (42.29M) | (41.95M) | (135.36M) | (126.15M) |
| Net Income | (1.25B) | (5.4B) | (1.47B) | (2.03B) | (408.35M) |
| Net Margin | -8539.4% | -9719.3% | -1574.2% | -1613.9% | -277.5% |
| EPS (Basic) | (40.18) | (173.87) | (47.20) | (63.54) | (11.11) |
| EPS (Diluted) | (40.18) | (173.87) | (47.20) | (63.54) | (11.11) |
| Weighted Avg Shares | 31.05M | 31.05M | 31.05M | 31.9M | 36.75M |
| Weighted Avg Shares (Diluted) | 31.05M | 31.05M | 31.05M | 31.9M | 36.75M |
GRAIL, Inc.
NASDAQ:GRAL
Intrinsic Alpha fair value
Locked
Current Price
$102.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.